Market Risers: AstraZeneca, DS Smith, EVRAZ, Experian

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Stock in AstraZeneca EPIC code: LON:AZN has increased 4.05% or 342 points during today’s session so far. Market buyers have remained optimistic during the session. The periods high has already touched 8788 and a low of 8538. The volume total for shares traded up to this point was 483,062 while the daily average number of shares exchanged is 2,025,728. The 52 week high price for the shares is 10120 some 1683 points difference from the previous days close and putting the 52 week low at 5871 which is a variance of 2566 points. AstraZeneca now has a 20 moving average of 8664.55 and also a 50 day moving average now of 8711.87. The current market capitalisation is £115,231.22m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca being recorded at Monday, August 24, 2020 at 1:08:28 PM GMT with the stock price trading at 8779 GBX.

The trading price for DS Smith found using EPIC: LON:SMDS has climbed 2.68% or 7.1 points during the course of today’s session so far. Market buyers have so far held a positive outlook throughout the trading session. The periods high has already touched 273.8 dropping as low as 267.6. The volume total for shares traded up to this point was 1,298,317 with the daily average traded share volume around 5,273,317. A 52 week share price high is 397.8 equating to 132.5 points in difference to the previous days close of business and a 52 week low sitting at 244.8 which is a difference of 20.5 points. DS Smith now has a 20 simple moving average of 283.26 and the 50 day MA at 297.27. The market cap now stands at £3,735.21m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for DS Smith being recorded at Monday, August 24, 2020 at 1:07:36 PM GMT with the stock price trading at 272.4 GBX.

The trading price for EVRAZ ticker lookup code: LON:EVR has gained 3.02% or 9.8 points throughout the session so far. Buyers have remained optimistic during the trading session. The period high has peaked at 336.8 dropping as low as 325.7. Volume total for shares traded at this point reached 747,498 with the daily average traded share volume around 2,643,894. A 52 week share price high is 547.6 amounting to 222.8 points difference from the previous close and the 52 week low at 200.6 a difference of some 124.2 points. EVRAZ now has a 20 simple moving average of 328.25 and now its 50 day simple moving average now at 313.09. Market capitalisation is now £4,874.70m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for EVRAZ being recorded at Monday, August 24, 2020 at 1:08:33 PM GMT with the stock price trading at 334.6 GBX.

Stock in Experian company symbol: LON:EXPN has gained 3.08% or 85 points during today’s session so far. Investors have stayed positive throughout the trading session. The periods high has already touched 2853 while the low for the session was 2778. The total volume of shares exchanged through this period comes to 219,225 whilst the daily average number of shares exchanged is just 1,365,231. The 52 week high for the shares is 2956 around 192 points difference from the previous close and the 52 week low at 1823.5 which is a variance of 940.5 points. Experian has a 20 day moving average of 2797.88 and now the 50 day SMA of 2836.27. The current market cap is £26,109.68m at the time of this report. The currency for this stock is Great British pence.Market cap is measured in GBP. This article was written with the last trade for Experian being recorded at Monday, August 24, 2020 at 1:07:34 PM GMT with the stock price trading at 2849 GBX.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials.
    AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival.

      Search

      Search